天壇生物(600161.SH):所屬漿站獲得單採血漿許可證
格隆匯 12 月 23日丨天壇生物(600161.SH)公佈,公司所屬蘭州蘭生血液製品有限公司永昌蘭生單採血漿有限責任公司於近日收到甘肅省衞生健康委員會簽發的《單採血漿許可證》。現將主要登記信息公告如下:
機構名稱:永昌蘭生單採血漿有限責任公司
地址:金昌市永昌縣南關收費站西側
登記號:MA73MPFT362032115F2009
業務項目:單採血漿
採漿範圍:金昌市、武威市、皇城鎮(張掖市肅南裕固族自治縣)
有效期限:自2020年12月21日至2022年12月20日
該單採血漿站經核准登記,准予執業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.